Home » Authors » Kim Coghill

Articles by Kim Coghill

Neurion's CNS Technologies Attracting Pharma Attention

July 10, 2003

Neurion's CNS Technologies Attracting Pharma Attention

July 10, 2003

Amgen Files With FDA Seeking Approval Of Enbrel In Psoriasis

July 9, 2003

Amgen Inc.'s Enbrel could be the first TNF blocker to make it to market as a treatment for psoriasis, an inflammatory disease often mischaracterized as a disease of the skin. (BioWorld Today)

Amgen Files With FDA Seeking Approval Of Enbrel In Psoriasis

July 9, 2003

Amgen Inc.'s Enbrel could be the first TNF blocker to make it to market as a treatment for psoriasis, an inflammatory disease often mischaracterized as a disease of the skin. (BioWorld Today)

Biotech Officials Huddling For Closer Look At Medicare Bills

July 7, 2003

Biotech Officials Huddling For Closer Look At Medicare Bills

July 7, 2003

ICOS, Lilly Finish Cialis NDA; FDA Accepts Additional Data

July 3, 2003

ICOS, Lilly Finish Cialis NDA; FDA Accepts Additional Data

July 3, 2003

Amgen Exercises Option, Gains Rights To Genmab's IL-15 Program

July 2, 2003

Amgen Exercises Option, Gains Rights To Genmab's IL-15 Program

July 2, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...